Nine months after the FDA froze simufilam’s development with a clinical hold request for additional preclinical data and protocol changes, Filana Therapeutics has cleared the regulatory obstacle and can now start enrolling patients in a Phase 2a proof-of-concept study in TSC-related epilepsy, a condition that affects more than four in five people diagnosed with tuberous sclerosis complex. The December 2025 hold cost the company the better part of a year; the lift, confirmed September 22, means the trial can proceed under a revised protocol that satisfied FDA’s preclinical data requirements.
Simufilam’s path to this point carries real baggage. The drug was originally developed by Cassava Sciences for Alzheimer’s disease, where it failed to hit co-primary, secondary, or exploratory biomarker endpoints across two Phase 3 trials, RETHINK-ALZ and REFOCUS-ALZ, leading Cassava to shut down that program entirely by early 2025. Filana is now pursuing a different indication entirely, betting that whatever biology simufilam engages is relevant to the seizure pathophysiology of TSC rather than Alzheimer’s neurodegeneration. That mechanistic pivot is unproven, and the Phase 2a study is explicitly a proof-of-concept read, not a registration-enabling trial.
TSC epilepsy is not without approved options. Everolimus (Afinitor Disperz) is approved as adjunctive therapy for partial-onset refractory seizures in patients two years and older, based on the EXIST-3 trial. The practical challenge is that a meaningful share of TSC patients continue to have refractory seizures despite mTOR inhibition and other available agents, which is presumably where Filana sees a clinical rationale for a drug with a distinct mechanism.
What the Phase 2a data will actually need to show is where the pressure sits now. A proof-of-concept study in a rare, mechanistically complex disease, using a compound that failed in a separate neurological indication, will require a clear signal in seizure frequency or a validated biomarker to justify advancing. The hold lift is a necessary procedural step; whether simufilam’s mechanism translates to TSC biology is the question the trial has to answer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
